Cargando…
Relapses in Patients With Giant Cell Arteritis: Prevalence, Characteristics, and Associated Clinical Findings in a Longitudinally Followed Cohort of 106 Patients
Giant cell arteritis (GCA) is a relapsing disease. However, the nature, chronology, therapeutic impact, and clinical consequences of relapses have been scarcely addressed. We conducted the present study to investigate the prevalence, timing, and characteristics of relapses in patients with GCA and t...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4602452/ https://www.ncbi.nlm.nih.gov/pubmed/25181312 http://dx.doi.org/10.1097/MD.0000000000000033 |
_version_ | 1782394720917389312 |
---|---|
author | Alba, Marco A. García-Martínez, Ana Prieto-González, Sergio Tavera-Bahillo, Itziar Corbera-Bellalta, Marc Planas-Rigol, Ester Espígol-Frigolé, Georgina Butjosa, Montserrat Hernández-Rodríguez, José Cid, Maria C. |
author_facet | Alba, Marco A. García-Martínez, Ana Prieto-González, Sergio Tavera-Bahillo, Itziar Corbera-Bellalta, Marc Planas-Rigol, Ester Espígol-Frigolé, Georgina Butjosa, Montserrat Hernández-Rodríguez, José Cid, Maria C. |
author_sort | Alba, Marco A. |
collection | PubMed |
description | Giant cell arteritis (GCA) is a relapsing disease. However, the nature, chronology, therapeutic impact, and clinical consequences of relapses have been scarcely addressed. We conducted the present study to investigate the prevalence, timing, and characteristics of relapses in patients with GCA and to analyze whether a relapsing course is associated with disease-related complications, increased glucocorticoid (GC) doses, and GC-related adverse effects. The study cohort included 106 patients, longitudinally followed by the authors for 7.8 ± 3.3 years. Relapses were defined as reappearance of disease-related symptoms requiring treatment adjustment. Relapses were classified into 4 categories: polymyalgia rheumatica (PMR), cranial symptoms (including ischemic complications), systemic disease, or symptomatic large vessel involvement. Cumulated GC dose during the first year of treatment, time required to achieve a maintenance prednisone dose <10 mg/d (T10), <5 mg/d (T5), or complete prednisone discontinuation (T0), and GC-related side effects were recorded. Sixty-eight patients (64%) experienced at least 1 relapse, and 38 (36%) experienced 2 or more. First relapse consisted of PMR in 51%, cranial symptoms in 31%, and systemic complaints in 18%. Relapses appeared predominantly, but not exclusively, within the first 2 years of treatment, and only 1 patient developed visual loss. T10, T5, and T0 were significantly longer in patients with relapses than in patients without relapse (median, 40 vs 27 wk, p < 0.0001; 163 vs 89.5 wk, p = 0.004; and 340 vs 190 wk, p = 0.001, respectively). Cumulated prednisone dose during the first year was significantly higher in relapsing patients (6.2 ± 1.7 g vs 5.4 ± 0.78 g, p = 0.015). Osteoporosis was more common in patients with relapses compared to those without (65% vs 32%, p = 0.001). In conclusion, the results of the present study provide evidence that a relapsing course is associated with higher and prolonged GC requirements and a higher frequency of osteoporosis in GCA. |
format | Online Article Text |
id | pubmed-4602452 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-46024522015-10-27 Relapses in Patients With Giant Cell Arteritis: Prevalence, Characteristics, and Associated Clinical Findings in a Longitudinally Followed Cohort of 106 Patients Alba, Marco A. García-Martínez, Ana Prieto-González, Sergio Tavera-Bahillo, Itziar Corbera-Bellalta, Marc Planas-Rigol, Ester Espígol-Frigolé, Georgina Butjosa, Montserrat Hernández-Rodríguez, José Cid, Maria C. Medicine (Baltimore) Article Giant cell arteritis (GCA) is a relapsing disease. However, the nature, chronology, therapeutic impact, and clinical consequences of relapses have been scarcely addressed. We conducted the present study to investigate the prevalence, timing, and characteristics of relapses in patients with GCA and to analyze whether a relapsing course is associated with disease-related complications, increased glucocorticoid (GC) doses, and GC-related adverse effects. The study cohort included 106 patients, longitudinally followed by the authors for 7.8 ± 3.3 years. Relapses were defined as reappearance of disease-related symptoms requiring treatment adjustment. Relapses were classified into 4 categories: polymyalgia rheumatica (PMR), cranial symptoms (including ischemic complications), systemic disease, or symptomatic large vessel involvement. Cumulated GC dose during the first year of treatment, time required to achieve a maintenance prednisone dose <10 mg/d (T10), <5 mg/d (T5), or complete prednisone discontinuation (T0), and GC-related side effects were recorded. Sixty-eight patients (64%) experienced at least 1 relapse, and 38 (36%) experienced 2 or more. First relapse consisted of PMR in 51%, cranial symptoms in 31%, and systemic complaints in 18%. Relapses appeared predominantly, but not exclusively, within the first 2 years of treatment, and only 1 patient developed visual loss. T10, T5, and T0 were significantly longer in patients with relapses than in patients without relapse (median, 40 vs 27 wk, p < 0.0001; 163 vs 89.5 wk, p = 0.004; and 340 vs 190 wk, p = 0.001, respectively). Cumulated prednisone dose during the first year was significantly higher in relapsing patients (6.2 ± 1.7 g vs 5.4 ± 0.78 g, p = 0.015). Osteoporosis was more common in patients with relapses compared to those without (65% vs 32%, p = 0.001). In conclusion, the results of the present study provide evidence that a relapsing course is associated with higher and prolonged GC requirements and a higher frequency of osteoporosis in GCA. Wolters Kluwer Health 2014-07-02 /pmc/articles/PMC4602452/ /pubmed/25181312 http://dx.doi.org/10.1097/MD.0000000000000033 Text en © 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins |
spellingShingle | Article Alba, Marco A. García-Martínez, Ana Prieto-González, Sergio Tavera-Bahillo, Itziar Corbera-Bellalta, Marc Planas-Rigol, Ester Espígol-Frigolé, Georgina Butjosa, Montserrat Hernández-Rodríguez, José Cid, Maria C. Relapses in Patients With Giant Cell Arteritis: Prevalence, Characteristics, and Associated Clinical Findings in a Longitudinally Followed Cohort of 106 Patients |
title | Relapses in Patients With Giant Cell Arteritis: Prevalence, Characteristics, and Associated Clinical Findings in a Longitudinally Followed Cohort of 106 Patients |
title_full | Relapses in Patients With Giant Cell Arteritis: Prevalence, Characteristics, and Associated Clinical Findings in a Longitudinally Followed Cohort of 106 Patients |
title_fullStr | Relapses in Patients With Giant Cell Arteritis: Prevalence, Characteristics, and Associated Clinical Findings in a Longitudinally Followed Cohort of 106 Patients |
title_full_unstemmed | Relapses in Patients With Giant Cell Arteritis: Prevalence, Characteristics, and Associated Clinical Findings in a Longitudinally Followed Cohort of 106 Patients |
title_short | Relapses in Patients With Giant Cell Arteritis: Prevalence, Characteristics, and Associated Clinical Findings in a Longitudinally Followed Cohort of 106 Patients |
title_sort | relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4602452/ https://www.ncbi.nlm.nih.gov/pubmed/25181312 http://dx.doi.org/10.1097/MD.0000000000000033 |
work_keys_str_mv | AT albamarcoa relapsesinpatientswithgiantcellarteritisprevalencecharacteristicsandassociatedclinicalfindingsinalongitudinallyfollowedcohortof106patients AT garciamartinezana relapsesinpatientswithgiantcellarteritisprevalencecharacteristicsandassociatedclinicalfindingsinalongitudinallyfollowedcohortof106patients AT prietogonzalezsergio relapsesinpatientswithgiantcellarteritisprevalencecharacteristicsandassociatedclinicalfindingsinalongitudinallyfollowedcohortof106patients AT taverabahilloitziar relapsesinpatientswithgiantcellarteritisprevalencecharacteristicsandassociatedclinicalfindingsinalongitudinallyfollowedcohortof106patients AT corberabellaltamarc relapsesinpatientswithgiantcellarteritisprevalencecharacteristicsandassociatedclinicalfindingsinalongitudinallyfollowedcohortof106patients AT planasrigolester relapsesinpatientswithgiantcellarteritisprevalencecharacteristicsandassociatedclinicalfindingsinalongitudinallyfollowedcohortof106patients AT espigolfrigolegeorgina relapsesinpatientswithgiantcellarteritisprevalencecharacteristicsandassociatedclinicalfindingsinalongitudinallyfollowedcohortof106patients AT butjosamontserrat relapsesinpatientswithgiantcellarteritisprevalencecharacteristicsandassociatedclinicalfindingsinalongitudinallyfollowedcohortof106patients AT hernandezrodriguezjose relapsesinpatientswithgiantcellarteritisprevalencecharacteristicsandassociatedclinicalfindingsinalongitudinallyfollowedcohortof106patients AT cidmariac relapsesinpatientswithgiantcellarteritisprevalencecharacteristicsandassociatedclinicalfindingsinalongitudinallyfollowedcohortof106patients |